# OnCo record paper-dawna-1-nat-med-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-dawna-1-nat-med-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-dawna-1-nat-med-2021" ;
  schema:name "Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial"@en ;
  schema:description "Published report from the DAWNA-1 trial registered as NCT03927456, in Nature Medicine (2021), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-dawna-1-nat-med-2021/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41591-021-01562-9>, <https://pubmed.ncbi.nlm.nih.gov/34737452/>, <https://europepmc.org/article/MED/34737452>, <https://clinicaltrials.gov/study/NCT03927456> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1038/s41591-021-01562-9> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Xu B, Zhang Q, Zhang P, et al." ;
  onco:trials <https://onco.cc/trials/dawna-1/> ;
  onco:journals <https://onco.cc/journals/nature-medicine/> .